144 related articles for article (PubMed ID: 16397281)
1. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
2. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
[TBL] [Abstract][Full Text] [Related]
4. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.
Prakash C; Johnson KA; Gardner MJ
Drug Metab Dispos; 2008 Jul; 36(7):1218-26. PubMed ID: 18372400
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
6. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment.
Zimmerman JJ; Patat A; Parks V; Moirand R; Matschke K
J Clin Pharmacol; 2008 Mar; 48(3):285-92. PubMed ID: 18218785
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
11. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
12. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Turncliff RZ; Dunbar JL; Dong Q; Silverman BL; Ehrich EW; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Nov; 45(11):1259-67. PubMed ID: 16239359
[TBL] [Abstract][Full Text] [Related]
15. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
19. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment.
Li Z; Gan LS; Marbury T; Lasseter KC; Natarajan A; Stecher S; Wei D; Yang L; Freedman D; Deykin A
J Clin Pharmacol; 2012 Apr; 52(4):543-51. PubMed ID: 21610206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
